Literature DB >> 19820929

Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer's disease.

Marie-Odile Habert1, Leonardo Cruz de Souza, Foudil Lamari, Nelle Daragon, Serge Desarnaud, Claude Jardel, Bruno Dubois, Marie Sarazin.   

Abstract

PURPOSE: Our aim was to study the correlations between cerebrospinal fluid (CSF) biomarker levels such as beta-amyloid 42 (Abeta(42)), total and phosphorylated tau protein (T-tau and P-tau) and brain perfusion SPECT in Alzheimer's disease (AD) using a voxel-based methodology.
METHODS: Patients (n = 31) with clinical features of AD (n = 25) or amnestic mild cognitive impairment (aMCI) (n = 6) were retrospectively included. All subjects underwent the same clinical, neuropsychological and neuroimaging tests. They had a lumbar puncture and a brain perfusion ((99m)Tc-ECD) SPECT within a time interval of 10 (+/-26) days. Correlations between CSF biomarker concentrations and perfusion were studied using SPM2 software. Individual normalised regional activity values were extracted from the eligible clusters for calculation of correlation coefficients.
RESULTS: No significant correlation was found between Abeta(42) concentrations and brain perfusion. A significant correlation (p < 0.01, corrected) was found between T-tau or P-tau concentrations and perfusion in the left parietal cortex.
CONCLUSION: Our results suggest a strong correlation between T-tau and P-tau levels and decreased brain perfusion in regions typically affected by neuropathological changes in AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19820929     DOI: 10.1007/s00259-009-1285-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  15 in total

1.  Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain.

Authors:  N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot
Journal:  Neuroimage       Date:  2002-01       Impact factor: 6.556

2.  Association between FDG uptake, CSF biomarkers and cognitive performance in patients with probable Alzheimer's disease.

Authors:  Sönke Arlt; Stefanie Brassen; Holger Jahn; Florian Wilke; Martin Eichenlaub; Ivayla Apostolova; Fabian Wenzel; Frank Thiele; Stewart Young; Ralph Buchert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-14       Impact factor: 9.236

3.  Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer's type, other types of dementia, and control subjects.

Authors:  M Tsolaki; V Sakka; G Gerasimou; N Dimacopoulos; O Chatzizisi; K N Fountoulakis; G Kyriazis; J Papanastasiou; A Kazis
Journal:  Am J Alzheimers Dis Other Demen       Date:  2001 Jan-Feb       Impact factor: 2.035

4.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Authors:  Henry Engler; Anton Forsberg; Ove Almkvist; Gunnar Blomquist; Emma Larsson; Irina Savitcheva; Anders Wall; Anna Ringheim; Bengt Långström; Agneta Nordberg
Journal:  Brain       Date:  2006-07-19       Impact factor: 13.501

5.  CSF neurofilament proteins in the differential diagnosis of dementia.

Authors:  D de Jong; R W M M Jansen; Y A L Pijnenburg; W J A van Geel; G F Borm; H P H Kremer; M M Verbeek
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02-21       Impact factor: 10.154

Review 6.  CSF markers for incipient Alzheimer's disease.

Authors:  Kaj Blennow; Harald Hampel
Journal:  Lancet Neurol       Date:  2003-10       Impact factor: 44.182

7.  Brain metabolic correlates of cerebrospinal fluid beta-amyloid 42 and tau in Alzheimer's disease.

Authors:  Ruth Vukovich; Robert Perneczky; Alexander Drzezga; Hans Förstl; Alexander Kurz; Matthias Riemenschneider
Journal:  Dement Geriatr Cogn Disord       Date:  2009-05-12       Impact factor: 2.959

8.  Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.

Authors:  Eric C Petrie; Donna J Cross; Douglas Galasko; Gerard D Schellenberg; Murray A Raskind; Elaine R Peskind; Satoshi Minoshima
Journal:  Arch Neurol       Date:  2009-05

Review 9.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Steven T Dekosky; Pascale Barberger-Gateau; Jeffrey Cummings; André Delacourte; Douglas Galasko; Serge Gauthier; Gregory Jicha; Kenichi Meguro; John O'brien; Florence Pasquier; Philippe Robert; Martin Rossor; Steven Salloway; Yaakov Stern; Pieter J Visser; Philip Scheltens
Journal:  Lancet Neurol       Date:  2007-08       Impact factor: 44.182

10.  CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease.

Authors:  R Ceravolo; D Borghetti; L Kiferle; G Tognoni; A Giorgetti; D Neglia; N Sassi; D Frosini; C Rossi; L Petrozzi; G Siciliano; L Murri
Journal:  Brain Res Bull       Date:  2008-02-11       Impact factor: 4.077

View more
  4 in total

1.  Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.

Authors:  Wei Tang; Qiong Huang; Yu-You Yao; Yan Wang; Yi-Le Wu; Zheng-Yu Wang
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

2.  Use of fuzzy edge single-photon emission computed tomography analysis in definite Alzheimer's disease--a retrospective study.

Authors:  Robert Rusina; Jaromír Kukal; Tomás Belícek; Marie Buncová; Radoslav Matej
Journal:  BMC Med Imaging       Date:  2010-09-01       Impact factor: 1.930

3.  Lower cerebral perfusion is associated with tau-PET in the entorhinal cortex across the Alzheimer's continuum.

Authors:  Anna Rubinski; Duygu Tosun; Nicolai Franzmeier; Julia Neitzel; Lukas Frontzkowski; Michael Weiner; Michael Ewers
Journal:  Neurobiol Aging       Date:  2021-02-10       Impact factor: 5.133

4.  Serum levels of proteins involved in amyloid-β clearance are related to cognitive decline and neuroimaging changes in mild cognitive impairment.

Authors:  Shan Liu; Hideaki Suzuki; Hitomi Ito; Tatsumi Korenaga; Hiroyasu Akatsu; Kohji Meno; Kazuhiko Uchida
Journal:  Alzheimers Dement (Amst)       Date:  2019-01-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.